Avunu Lifesciences

Avunu is a preclinical-stage biotechnology company dedicated to discovering and developing first-in-class small molecule therapeutics for cancer and autoimmune diseases. The company's primary focus is on targeting MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), a key mediator in the NF-kB signaling pathway that is often dysregulated in various lymphomas. By leveraging deep expertise in chemical biology and oncology, Avunu is advancing a pipeline of potent and selective MALT1 inhibitors designed to overcome resistance in aggressive B-cell malignancies. Headquartered in Ann Arbor, Michigan, the company was founded by world-renowned researchers from the University of Michigan.